DK3416957T3 - 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes - Google Patents
6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes Download PDFInfo
- Publication number
- DK3416957T3 DK3416957T3 DK17704791.7T DK17704791T DK3416957T3 DK 3416957 T3 DK3416957 T3 DK 3416957T3 DK 17704791 T DK17704791 T DK 17704791T DK 3416957 T3 DK3416957 T3 DK 3416957T3
- Authority
- DK
- Denmark
- Prior art keywords
- ylpyridin
- morpholin
- heterocyclyl
- diabetes
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16156533 | 2016-02-19 | ||
| PCT/EP2017/053614 WO2017140843A1 (en) | 2016-02-19 | 2017-02-17 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3416957T3 true DK3416957T3 (da) | 2020-09-21 |
Family
ID=55404646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17704791.7T DK3416957T3 (da) | 2016-02-19 | 2017-02-17 | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11179399B2 (da) |
| EP (1) | EP3416957B1 (da) |
| JP (1) | JP6858984B2 (da) |
| CN (1) | CN108884067B (da) |
| AU (1) | AU2017219847B2 (da) |
| CA (1) | CA3015005A1 (da) |
| CY (1) | CY1123349T1 (da) |
| DK (1) | DK3416957T3 (da) |
| ES (1) | ES2821400T3 (da) |
| HR (1) | HRP20201430T1 (da) |
| HU (1) | HUE051059T2 (da) |
| LT (1) | LT3416957T (da) |
| PL (1) | PL3416957T3 (da) |
| PT (1) | PT3416957T (da) |
| RS (1) | RS60900B1 (da) |
| RU (1) | RU2762968C2 (da) |
| SI (1) | SI3416957T1 (da) |
| SM (1) | SMT202000529T1 (da) |
| TW (1) | TWI723131B (da) |
| WO (1) | WO2017140843A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3015005A1 (en) * | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
| CA3073142A1 (en) * | 2017-08-23 | 2019-02-28 | Sprint Bioscience Ab | Morpholinylpyridone compounds |
| EP3672967B1 (en) | 2017-08-23 | 2021-10-06 | Sprint Bioscience AB | Azaindolylpyridone and diazaindolylpyridone compounds |
| DK3672948T3 (da) | 2017-08-23 | 2022-12-05 | Sprint Bioscience Ab | Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser |
| ES2910839T3 (es) | 2017-08-23 | 2022-05-13 | Sprint Bioscience Ab | Compuestos de piridilpiridona |
| CA3094714A1 (en) | 2018-04-10 | 2019-10-17 | Neuropore Therapies, Inc. | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
| EP3774792B1 (en) | 2018-04-10 | 2022-09-14 | Neuropore Therapies, Inc. | Morpholine derivates as inhibitors of vps34 |
| WO2020008046A1 (en) | 2018-07-06 | 2020-01-09 | Sprint Bioscience Ab | Biomarker |
| US11685734B2 (en) * | 2019-12-04 | 2023-06-27 | Chdi Foundation, Inc. | ATM kinase inhibitors and compositions and methods of use thereof |
| CA3199988A1 (en) | 2020-11-25 | 2022-06-02 | Daniel L. Flynn | Pyridylpyridone derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
| JP2023550638A (ja) * | 2020-11-25 | 2023-12-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | ウイルス感染症の処置に使用するための、ｖｓｐ３４阻害剤としてのモルホリノ誘導体 |
| CA3228766A1 (en) | 2021-08-13 | 2023-02-16 | Yasmin YU | Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1575940B1 (en) | 2002-11-21 | 2011-10-05 | Novartis AG | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| MY155661A (en) | 2009-07-02 | 2015-11-13 | Sanofi Sa | Novel 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives, preparation thereof and pharmaceutical use thereof |
| KR20130130030A (ko) | 2010-12-21 | 2013-11-29 | 노파르티스 아게 | Vps34 억제제로서의 비-헤테로아릴 화합물 |
| EP2655375B1 (fr) | 2010-12-23 | 2014-12-03 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| FR2992314B1 (fr) * | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2015030057A1 (ja) * | 2013-08-29 | 2015-03-05 | 富士フイルム株式会社 | 新規なモルホリン誘導体またはその塩 |
| WO2015108861A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| PT3416945T (pt) * | 2016-02-19 | 2020-09-11 | Sprint Bioscience Ab | Compostos de 6-aril-4-(morfolin-4-il)-1h-piridina-2-ona úteis para o tratamento do cancro e da diabetes |
| CA3015005A1 (en) * | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
-
2017
- 2017-02-17 CA CA3015005A patent/CA3015005A1/en active Pending
- 2017-02-17 EP EP17704791.7A patent/EP3416957B1/en active Active
- 2017-02-17 JP JP2018562702A patent/JP6858984B2/ja active Active
- 2017-02-17 ES ES17704791T patent/ES2821400T3/es active Active
- 2017-02-17 AU AU2017219847A patent/AU2017219847B2/en active Active
- 2017-02-17 TW TW106105178A patent/TWI723131B/zh not_active IP Right Cessation
- 2017-02-17 PT PT177047917T patent/PT3416957T/pt unknown
- 2017-02-17 SI SI201730405T patent/SI3416957T1/sl unknown
- 2017-02-17 HU HUE17704791A patent/HUE051059T2/hu unknown
- 2017-02-17 RU RU2018131766A patent/RU2762968C2/ru active
- 2017-02-17 WO PCT/EP2017/053614 patent/WO2017140843A1/en active Application Filing
- 2017-02-17 LT LTEP17704791.7T patent/LT3416957T/lt unknown
- 2017-02-17 SM SM20200529T patent/SMT202000529T1/it unknown
- 2017-02-17 CN CN201780015103.7A patent/CN108884067B/zh active Active
- 2017-02-17 PL PL17704791T patent/PL3416957T3/pl unknown
- 2017-02-17 RS RS20201061A patent/RS60900B1/sr unknown
- 2017-02-17 DK DK17704791.7T patent/DK3416957T3/da active
- 2017-02-17 US US15/999,432 patent/US11179399B2/en active Active
-
2020
- 2020-09-08 HR HRP20201430TT patent/HRP20201430T1/hr unknown
- 2020-09-15 CY CY20201100870T patent/CY1123349T1/el unknown
-
2021
- 2021-10-14 US US17/501,407 patent/US11963963B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017219847A1 (en) | 2018-10-04 |
| RU2018131766A (ru) | 2020-03-20 |
| LT3416957T (lt) | 2020-11-25 |
| ES2821400T3 (es) | 2021-04-26 |
| RU2018131766A3 (da) | 2020-03-24 |
| US20220175788A1 (en) | 2022-06-09 |
| TWI723131B (zh) | 2021-04-01 |
| TW201731843A (zh) | 2017-09-16 |
| PL3416957T3 (pl) | 2021-02-08 |
| WO2017140843A1 (en) | 2017-08-24 |
| US11963963B2 (en) | 2024-04-23 |
| HUE051059T2 (hu) | 2021-03-01 |
| CN108884067B (zh) | 2021-01-08 |
| EP3416957A1 (en) | 2018-12-26 |
| JP6858984B2 (ja) | 2021-04-14 |
| SMT202000529T1 (it) | 2020-11-10 |
| CY1123349T1 (el) | 2021-12-31 |
| JP2019505595A (ja) | 2019-02-28 |
| US20210161906A1 (en) | 2021-06-03 |
| HRP20201430T1 (hr) | 2020-11-27 |
| RS60900B1 (sr) | 2020-11-30 |
| AU2017219847B2 (en) | 2021-02-04 |
| EP3416957B1 (en) | 2020-07-01 |
| PT3416957T (pt) | 2020-09-25 |
| CA3015005A1 (en) | 2017-08-24 |
| CN108884067A (zh) | 2018-11-23 |
| US11179399B2 (en) | 2021-11-23 |
| RU2762968C2 (ru) | 2021-12-24 |
| SI3416957T1 (sl) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3733187T3 (da) | Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| DK3416945T3 (da) | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3432899T3 (da) | Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| DK3556383T5 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
| DK3532067T3 (da) | Liposomal formulering til anvendelse til behandling af cancer | |
| DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte | |
| DK2991507T3 (da) | Anvendelse af en sammensætning omfattende fiskeolie og juice til behandling og/eller efterbehandling af cancer | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3551189T3 (da) | Alprazolam til anvendelse ved behandling af epilepsi | |
| DK3174559T3 (da) | Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer | |
| DK3258964T3 (da) | Detektion og behandling af maligne tumorer i CNS | |
| DK3442558T3 (da) | Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis |